跳至主要内容
临床试验/NCT01909908
NCT01909908终止不适用

Treatment of Chronic Wounds Using Extracellular Matrix-Based Devices and the Patient's Own Blood Components

Cook Group Incorporated2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2013年2月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
2
试验地点
2
主要终点
Incidence of adverse events

研究概览

简要总结

The Extracellular Matrix (ECM) and Blood Components for Wound Healing feasibility study is a clinical trial approved by Health Canada to study the safety of extracellular matrix (ECM) and autologous blood products in wound healing.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 or Type 2 diabetes, and/or venous insufficiency to the affected leg
  • Ulcer has been present between 12 and 52 weeks
  • Ulcer is less than 40 cm2 in area

排除标准

  • Less than 18 years of age
  • Pregnant or planning to become pregnant during the study period
  • Simultaneously participating in another investigational drug or device study
  • Unable or unwilling to comply with the weekly study follow-up schedule or off-loading regimen
  • Patient or legal representative refuses to sign the EC-approved informed consent form
  • Known allergy to pig or porcine products
  • Additional criteria may apply

结局指标

主要结局

Incidence of adverse events

时间窗: 12 weeks

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

ECM and Blood Components for Wound Healing | 临床试验